References
- Paoletti E, De Nicola L, Gabbai FB, et al. Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol. 2016;11(2):271–279.
- Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335.
- Locatelli F, Bárány P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–1359.
- Chen H, Cheng Q, Wang J, et al., Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients. J Clin Pharm Ther. 2021;46(4): 999–1009.
- Tóth Tóth A, Csiki DM Jr, Nagy B, et al. Daprodustat accelerates high phosphate-induced calcification through the activation of HIF-1 signaling. Front Pharmacol. 2022;13:798053.
- Wang S, Zhao L, Liu H, et al. Lanthanum hydroxide inhibits vascular calcification by regulating the HIF-1 pathway. Cell Biol Int. 2022;46(8):187–1275.
- Chertow GM, Pergola PE, Farag YMK, et al. PRO2TECT Study Group. Vadadustat in patients with anemia and non–dialysis-dependent CKD. N Engl J Med. 2021;384(17):1589–1600
- Xiong L, Zhang H, Guo Y, et al. Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis. Front Pharmacol. 2022;12:795214.
- Pilli VS, Datta A, Afreen S, et al. Hypoxia downregulates protein S expression. Blood. 2018;132(4):452–455.
- Singh AK, Carroll K, McMurray JJV, et al., ASCEND-ND study group. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med. 2021;385(25): 2313–2324.
- Akizawa T, Nangaku M, Yonekawa T, et al., Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomised, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020;15(8): 1155–1165.
- Tokuyama A, Kadoya H, Obata A, et al. Roxadustat and thyroid-stimulating hormone suppression. Clin Kidney J. 2021;14(5):1472–1474.
- Shutov E, Sułowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (Alps). Nephrol Dial Transplant. 2021;36(9):1629–1639.
- Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a Randomized Phase 3 Study. J Am Soc Nephrol. 2021;32(3):737–755.
- Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36(9):1616–1628.